Sunday, October 6, 2024
Home Oncology & Cancer Tool to study new treatments for liver cancer

Tool to study new treatments for liver cancer

by Medical Xpress
0 comment


HepYF-13 cells form ectopic tumors in syngeneic hosts. Credit: Disease Models & Mechanisms (2024). DOI: 10.1242/dmm.050553

A team led by Sylvain Meloche, Professor in the Faculty of Medicine at UdeM and Director of IRIC’s Signaling and Cell Growth Research Unit, has developed a new preclinical model for the study of the most common subtype of liver cancer.

Published in the journal Disease Models & Mechanisms, the work was carried out by research associate Laure Voisin and research advisor Marjorie Lapouge. Vincent Quoc-HuyTrinh, Director of IRIC’s Digital Histology and Advanced Pathology Research Unit, also contributed to the study.

In search of a clinically relevant study model

Liver cancer is a major health issue worldwide: the sixth most common cancer, and the third most deadly. One subtype in particular, (HCC), accounts for 80%–90% of liver cancers. Often diagnosed at an and ineffectively targeted by the few existing treatments, HCC does not offer a favorable prognosis for patients.

The Meloche laboratory team set out to fill an essential need in the identification of new therapies targeting HCC: the development of a preclinical model mimicking advanced human HCC as accurately as possible. To achieve this, the team established a cell line from genetically modified murine liver tumors: the HepYF line.

HepYF: A model that reproduces the pathophysiological features of aggressive and metastatic HCC

Several advantages make the HepYF line a good model for studying liver cancers. It generates tumors that grow rapidly, predictably and reproducibly, and are representative of the most aggressive forms of metastatic HCC.

Furthermore, the HepYF line offers a syngeneic model: It is derived from murine specimens that possess the same genetic background as those into which it will be injected for carcinogenesis analyses or preclinical studies. Perceived as “self” by the , it is one of the few models that can be used to analyze the against the tumor and evaluate immunotherapy options.

Thanks to these characteristics, the HepYF developed by the Meloche laboratory will enable a better understanding of HCC pathogenesis. It will also be very useful for testing new molecules and immunotherapies that could improve the range of treatments available for cancers.

More information:
Laure Voisin et al, Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma, Disease Models & Mechanisms (2024). DOI: 10.1242/dmm.050553

Citation:
Tool to study new treatments for liver cancer (2024, September 18)
retrieved 18 September 2024
from https://medicalxpress.com/news/2024-09-tool-treatments-liver-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

You may also like

Leave a Comment

Edtior's Picks

Latest Articles

All Rights reserved, site designed by Yellohost.co.za